{
  "alleleExist":false,
  "dataVersion":"v4.5",
  "diagnosticImplications":[],
  "diagnosticSummary":"",
  "geneExist":true,
  "geneSummary":"SMAD4 encodes a tumor suppressor and transcription factor that is a downstream effector in the TGF-\u00df signal transduction pathway. SMAD4 is frequently mutated in pancreatic and colorectal cancer and infrequently mutated in various other cancers.",
  "highestDiagnosticImplicationLevel":null,
  "highestFdaLevel":null,
  "highestPrognosticImplicationLevel":null,
  "highestResistanceLevel":null,
  "highestSensitiveLevel":null,
  "hotspot":false,
  "lastUpdate":"04/07/2017",
  "mutationEffect":{
    "citations":{
      "abstracts":[],
      "pmids":[
        "23139211",
        "10340381",
        "11553622",
        "15711891",
        "9094310"
      ]
    },
    "description":"Truncating mutations in SMAD4 typically occur in the M2 domain are associated with loss of protein function (PMID: 23139211). Truncating variants disrupting or lacking the MH2 domain can abrogate the ability of SMAD4 to form multimeric SMAD complexes and active DNA-binding complexes (PMID: 11553622, 10340381, 9094310) and these alterations have shown to abrogate growth-inhibiting TGF\u00df signaling (PMID: 15711891).",
    "knownEffect":"Likely Loss-of-function"
  },
  "oncogenic":"Likely Oncogenic",
  "otherSignificantResistanceLevels":[],
  "otherSignificantSensitiveLevels":[],
  "prognosticImplications":[],
  "prognosticSummary":"",
  "query":{
    "alteration":"S343*",
    "alterationType":null,
    "consequence":"stop_gained",
    "entrezGeneId":4089,
    "hgvs":null,
    "hugoSymbol":"SMAD4",
    "id":null,
    "proteinEnd":343,
    "proteinStart":343,
    "referenceGenome":"GRCh38",
    "svType":null,
    "tumorType":null
  },
  "treatments":[],
  "tumorTypeSummary":"",
  "variantExist":false,
  "variantSummary":"The SMAD4 S343* mutation is likely oncogenic.",
  "vus":false
}